Navigation Links
Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
Date:4/2/2013

SEATTLE, April 2, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in a well-established animal model of thrombotic microangiopathy (TMA), a disorder that occurs in the microcirculation (e.g., venules and capillaries) of the body's organs, most commonly the kidney and brain. Omeros expects to submit a European Clinical Trial Application (CTA) this quarter to initiate clinical trials evaluating OMS721.  The lead indication planned for OMS721 clinical trials is atypical hemolytic uremic syndrome (aHUS), a rare but life-threatening form of TMA.

Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein involved in activation of the complement system – an important component of the immune system. The complement system plays a role in the inflammatory response to tissue damage or microbial infection. OMS721 selectively inhibits MASP-2, blocking the lectin pathway of the complement system while leaving intact the classical pathway, or the acquired immune response to infection. The Company has conducted a series of preclinical studies that suggest that MASP-2 inhibition may have a preventive or therapeutic effect in the treatment of aHUS, HUS, wet age-related macular degeneration (AMD), paroxysmal nocturnal hemoglobinuria (PNH), transplant-related complications, ischemia-reperfusion injury, and other immune-related disorders.

The studies reported today were conducted to support the planned initial indication for OMS721 – aHUS. In this well-established model, thrombus (blood clot) formation is induced in microvessels following phototoxic injury of the vessel wall. Using intravital microscopy, a high-resolution im
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... JUNCTION, N.J. , Jan. 23, 2015  CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... patients, announced the receipt of $385,642, net of ... participant of the Technology Business Tax Certificate Transfer ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced ... have been enrolled into the Company,s Phase 2 clinical ... safety of Gem,s lead compound, GPX-150 (an investigational medication), ... or metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/23/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... development and sale of patented biopharmaceutical medicine, modernized traditional ... (API) today announced the business and development progress at ... 1. Following the September 2014 JCM application (No. 51268) ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... 2011 Progressive Medical, Inc., a leading pharmacy benefit ... compensation and no-faulty auto industries, has named Kevin Banion ... current role as president of Progressive Medical. This strategic ... that David Bianconi recently announced that he will serve ...
... Jan. 19, 2011 QBC Diagnostics is pleased to ... breakthrough product that can easily upgrade any compound light ... Advance builds on the proven success of the ParaLens ... LED fluorescence microscopy to thousands of labs around the ...
Cached Medicine Technology:Kevin Banion Named CEO of Progressive Medical, Inc. 2QBC Diagnostics Announces the Availability of the ParaLens Advance LED Fluorescence Microscopy Attachment 2
(Date:1/22/2015)... January 22, 2015 The City of West Hollywood ... a.m., to commemorate the 42nd anniversary of the Supreme Court decision ... “It’s been 42 years since the Roe vs. Wade decision and ... as present as ever,” said City of West Hollywood Councilmember Abbe ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the ... , Purchasing an accidental death and dismemberment rider for ... of rider provides benefits if the insured dies in an ... form of life insurance. , AD&D is not expensive ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 IsoComforter, Inc. has ... machine with patented IsoTube design to treat specific body parts ... the most progressive and easy to use patented cold therapy ... and sports related orthopedic and muscle injuries. IsoComforter has ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... The Cystic Fibrosis Foundation announced today that VX-770, an ... in CF, showed promising results in an ongoing Phase ... mutation of CF. The drug is being developed by ... for 14 days showed significant improvements in several key ...
... improved access to health education and benefits for ... seniors in communities across America, ... in Washington, D.C., CVS/pharmacy and the National Council on Aging,(NCOA) ... health and well-being of older Americans. Their joint,"Prescription for Better ...
... Recognizes Visionary Advocate, LOS ANGELES, March 27 ... Gregg Gonsalves has been selected as the,first-ever recipient of ... An AIDS activist for 17 years, Gonsalves has played ... and improve access to,lifesaving drugs. He is currently based ...
... women die from breast cancer each year because current ... fail to stem the disease, warns Breast Cancer Campaign ... research published today, 56 of the UKs most influential ... and priorities for the greatest potential impact on patients. ...
... Poll: Teens Still Feel Targeted By Tobacco Advertising and ... Kids across Virginia,will rally against tobacco on April ... the 13th annual Kick Butts Day, sponsored by the,Campaign ... the,nation (for a list of local events, go to, ...
... VANCOUVER, March 27 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM:TSX-V) announced ... in Denver, CO. This Center is the Company,s first ... CRH has targeted for expansion. The,opening of the Denver ... According to the National Institute of Health, the ...
Cached Medicine News:Health News:Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770 2Health News:CVS/pharmacy and the National Council on Aging Extend 'Prescription for Better Health' Partnership 2Health News:CVS/pharmacy and the National Council on Aging Extend 'Prescription for Better Health' Partnership 3Health News:AIDS Activist Gregg Gonsalves Receives $100,000 Leadership Award 2Health News:AIDS Activist Gregg Gonsalves Receives $100,000 Leadership Award 3Health News:Too many women still dying from breast cancer, says charity 2Health News:Virginia Kids 'Kick Butts' on April 2 2Health News:Virginia Kids 'Kick Butts' on April 2 3Health News:CRH Medical Corporation opens new center in Denver, Colorado 2
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
Medicine Products: